These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 10065779

  • 1. Adrenal dynamic responses to physiologic and pharmacologic adrenocorticotropic hormone stimulation before and after ovarian steroid modulation in women with polycystic ovary syndrome.
    Gonzalez F, Chang L, Horab T, Stanczyk FZ, Crickard K, Lobo RA.
    Fertil Steril; 1999 Mar; 71(3):439-44. PubMed ID: 10065779
    [Abstract] [Full Text] [Related]

  • 2. 17-Hydroxyprogesterone responses to gonadotrophin-releasing hormone agonist buserelin and adrenocorticotrophin in polycystic ovary syndrome: investigation of adrenal and ovarian cytochrome P450c17alpha dysregulation.
    Sahin Y, Keleştimur F.
    Hum Reprod; 1997 May; 12(5):910-3. PubMed ID: 9194638
    [Abstract] [Full Text] [Related]

  • 3. 17-hydroxyprogesterone responses to gonadotropin-releasing hormone disclose distinct phenotypes of functional ovarian hyperandrogenism and polycystic ovary syndrome.
    Pasquali R, Patton L, Pocognoli P, Cognigni GE, Gambineri A.
    J Clin Endocrinol Metab; 2007 Nov; 92(11):4208-17. PubMed ID: 17785360
    [Abstract] [Full Text] [Related]

  • 4. Normal ovulatory women with polycystic ovaries have hyperandrogenic pituitary-ovarian responses to gonadotropin-releasing hormone-agonist testing.
    Chang PL, Lindheim SR, Lowre C, Ferin M, Gonzalez F, Berglund L, Carmina E, Sauer MV, Lobo RA.
    J Clin Endocrinol Metab; 2000 Mar; 85(3):995-1000. PubMed ID: 10720029
    [Abstract] [Full Text] [Related]

  • 5. Hyperandrogenism in women with polycystic ovary syndrome persists after menopause.
    Markopoulos MC, Rizos D, Valsamakis G, Deligeoroglou E, Grigoriou O, Chrousos GP, Creatsas G, Mastorakos G.
    J Clin Endocrinol Metab; 2011 Mar; 96(3):623-31. PubMed ID: 21177795
    [Abstract] [Full Text] [Related]

  • 6. Gonadotrophin and gonadal steroid response to a single dose of a long-acting agonist of gonadotrophin-releasing hormone in ovulatory and anovulatory women with polycystic ovary syndrome.
    White D, Leigh A, Wilson C, Donaldson A, Franks S.
    Clin Endocrinol (Oxf); 1995 May; 42(5):475-81. PubMed ID: 7621565
    [Abstract] [Full Text] [Related]

  • 7. A comparison between the effects of low dose (1 microg) and standard dose (250 microg) ACTH stimulation tests on adrenal P450c17alpha enzyme activity in women with polycystic ovary syndrome.
    Colak R, Keleştimur F, Unlühizarci K, Bayram F, Sahin Y, Tutuş A.
    Eur J Endocrinol; 2002 Oct; 147(4):473-7. PubMed ID: 12370108
    [Abstract] [Full Text] [Related]

  • 8. Ovarian 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone (GnRH) agonist challenge in women with polycystic ovary syndrome is not mediated by luteinizing hormone hypersecretion: evidence from GnRH agonist and human chorionic gonadotropin stimulation testing.
    Ibañez L, Hall JE, Potau N, Carrascosa A, Prat N, Taylor AE.
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4103-7. PubMed ID: 8923867
    [Abstract] [Full Text] [Related]

  • 9. Androgen responses to adrenocorticotropic hormone infusion among individual women with polycystic ovary syndrome.
    Maas KH, Chuan S, Harrison E, Cook-Andersen H, Duleba AJ, Chang RJ.
    Fertil Steril; 2016 Oct; 106(5):1252-1257. PubMed ID: 27473350
    [Abstract] [Full Text] [Related]

  • 10. Evidence for heterogeneous etiologies of adrenal dysfunction in polycystic ovary syndrome.
    Gonzalez F, Chang L, Horab T, Lobo RA.
    Fertil Steril; 1996 Sep; 66(3):354-61. PubMed ID: 8751729
    [Abstract] [Full Text] [Related]

  • 11. Ovarian-adrenal cross-talk in polycystic ovary syndrome: evidence from wedge resection.
    Wu XK, Zhou SY, Sallinen K, Pöllänen P, Erkkola R.
    Eur J Endocrinol; 2000 Sep; 143(3):383-8. PubMed ID: 11022181
    [Abstract] [Full Text] [Related]

  • 12. Ovarian influence on adrenal androgen secretion in polycystic ovary syndrome.
    Fruzzetti F, De Lorenzo D, Ricci C, Teti G.
    Fertil Steril; 1995 Apr; 63(4):734-41. PubMed ID: 7890056
    [Abstract] [Full Text] [Related]

  • 13. Adrenocortical hyperresponsiveness to corticotropin in polycystic ovary syndrome patients with adrenal androgen excess.
    Moran C, Reyna R, Boots LS, Azziz R.
    Fertil Steril; 2004 Jan; 81(1):126-31. PubMed ID: 14711555
    [Abstract] [Full Text] [Related]

  • 14. Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome.
    Nestler JE, Jakubowicz DJ.
    N Engl J Med; 1996 Aug 29; 335(9):617-23. PubMed ID: 8687515
    [Abstract] [Full Text] [Related]

  • 15. Effects of metformin on adrenal steroidogenesis in women with polycystic ovary syndrome.
    la Marca A, Morgante G, Paglia T, Ciotta L, Cianci A, De Leo V.
    Fertil Steril; 1999 Dec 29; 72(6):985-9. PubMed ID: 10593368
    [Abstract] [Full Text] [Related]

  • 16. Adrenal and ovarian steroid hormone responses to gonadotropin-releasing hormone agonist treatment in polycystic ovary syndrome.
    Gonzalez F, Hatala DA, Speroff L.
    Am J Obstet Gynecol; 1991 Sep 29; 165(3):535-45. PubMed ID: 1832519
    [Abstract] [Full Text] [Related]

  • 17. Adrenal androgen excess in the polycystic ovary syndrome: sensitivity and responsivity of the hypothalamic-pituitary-adrenal axis.
    Azziz R, Black V, Hines GA, Fox LM, Boots LR.
    J Clin Endocrinol Metab; 1998 Jul 29; 83(7):2317-23. PubMed ID: 9661602
    [Abstract] [Full Text] [Related]

  • 18. Effect of pioglitazone treatment on the adrenal androgen response to corticotrophin in obese patients with polycystic ovary syndrome.
    Guido M, Romualdi D, Suriano R, Giuliani M, Costantini B, Apa R, Lanzone A.
    Hum Reprod; 2004 Mar 29; 19(3):534-9. PubMed ID: 14998947
    [Abstract] [Full Text] [Related]

  • 19. Pituitary function is altered during the same cycle in women with polycystic ovary syndrome treated with continuous or cyclic oral contraceptives or a gonadotropin-releasing hormone agonist.
    Ruchhoft EA, Elkind-Hirsch KE, Malinak R.
    Fertil Steril; 1996 Jul 29; 66(1):54-60. PubMed ID: 8752611
    [Abstract] [Full Text] [Related]

  • 20. Low dose ketoconazole attenuates serum androgen levels in patients with polycystic ovary syndrome and inhibits ovarian steroidogenesis in vitro.
    Gal M, Orly J, Barr I, Algur N, Boldes R, Diamant YZ.
    Fertil Steril; 1994 May 29; 61(5):823-32. PubMed ID: 8174717
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.